Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders. The conventional chemotherapy methods are being replaced by more convenient therapeutic radiopharmaceuticals for oncology and cancer treatment, which opens up new avenues in the radiopharmaceuticals market. Moreover, it not only helps physicians during diagnosis, but also works as a convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Radiopharmaceuticals, also known as nuclear medicines, are used in applications such as lymphoma and bone metastasis. F-18, Tc-99, Ga-67, and I-123 are some of the nuclear medicines used in diagnostic procedures, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures.
The world radiopharmaceuticals market is expected to generate a revenue of $8,207.5 million by 2022, the market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine. Convenience of the treatment with minimally invasive techniques attracts more patients towards radiopharmaceuticals mode of treatment as compared to chemotherapy. The factors that drive the Radiopharmaceuticals Industry include increasing incidence of cardiac patients and adoption of clear imaging technique, with the help of diagnostic equipment such as PET and SPECT. The factors that restrain the growth of the market include supply shortages, logistical difficulties, and limited number of trained medical personnel.
The report segments the radiopharmaceuticals industry on the basis of type, modality, application, end user, and geography. On the basis of type, the market is segmented into diagnostic, therapeutic, and research. Based on modality, the nuclear medicine market is segregated into SPECT, PET, alpha emitters, beta emitters, and brachytherapy. According to application, the market is classified into oncology, cardiology, neurology, thyroid, and others. The geographic breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific is the highest revenue generating region accounting for about 35.1% of the total market and is projected to grow at a high CAGR of 8.4% during the forecast period.
Comprehensive competitive analysis and profiles of major market players such as Mallinckrodt plc., General Electric Co. (healthcare division), Medtronic, Inc., Bayer AG, Cardinal Health, Inc., Lantheus Medical Imaging, Inc., and IBA Group is also provided in this report.
KEY BENEFITS FOR STAKEHOLDERS:
NEUCLEAR MEDICINE/ RADIOPAHRMACEUTICALS MARKET KEY SEGMENTS:
SIMILAR MARKET STUDIES
Summary Bristol-Myers Squibb Company (BMS) is specialty biopharmaceutical company, which focuses on innovative drugs to address unmet medical needs of patients with serious diseases. It discovers, develops, licenses, manufactures, markets and distributes biopharmaceuticals and related healthcare products. Its product line includes chemically-synthesized drugs and biological products in the areas of cancer, ...
October 2016 | $250 | View Details >>
This report mainly covers the following Product types including Allogeneic stem cell Autologous stem cell The segment applications including Autoimmune?Disease Immunodeficiencies Malignancies,Caners Solid?Tumor Others Segment regions including (the separated region report can ...
June 2016 | $3500 | View Details >>
The Global and China Bivalirudin Market Research Report Forecast 2017-2021 is a valuable source of insightful data for business strategists. It provides the Bivalirudin industry overview with growth analysis and historical & futuristic cost, revenue, demand and supply data (as applicable). The research analysts provide an elaborate description of the ...
May 2017 | $2700 | View Details >>
DelveInsight’s “Sarcopenia - Epidemiology Forecast To 2023” Report provides an overview of the epidemiology trends of Sarcopenia in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes historical and forecasted epidemiological data for the prevalent cases of Sarcopenia from 2013-2023. Sarcopenia is the progressive loss of skeletal ...
April 2017 | $2750 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research